Cargando…

The glucagon‐like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents

The incretin hormone, glucagon‐like peptide 1 (GLP‐1), regulates gastric emptying, glucose‐dependent stimulation of insulin secretion and glucagon release, and GLP‐1 analogs are therefore approved for treatment of type II diabetes. GLP‐1 receptors are expressed in reward‐related areas such as the ve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vallöf, Daniel, Maccioni, Paola, Colombo, Giancarlo, Mandrapa, Minja, Jörnulf, Julia Winsa, Egecioglu, Emil, Engel, Jörgen A., Jerlhag, Elisabet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Preclinical Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049632/ https://www.ncbi.nlm.nih.gov/pubmed/26303264 http://dx.doi.org/10.1111/adb.12295

Ejemplares similares

Central administration of the anorexigenic peptide neuromedin U decreases alcohol intake and attenuates alcohol‐induced reward in rodents
por: Vallöf, Daniel, et al.
Publicado: (2016)

Activation of amylin receptors attenuates alcohol‐mediated behaviours in rodents
por: Kalafateli, Aimilia Lydia, et al.
Publicado: (2018)

Glutamatergic regulation of ghrelin-induced activation of the mesolimbic dopamine system
por: Jerlhag, Elisabet, et al.
Publicado: (2011)

Brain region‐specific neuromedin U signalling regulates alcohol‐related behaviours and food intake in rodents
por: Vallöf, Daniel, et al.
Publicado: (2019)

The Glucagon-Like Peptide 1 Analogue, Exendin-4, Attenuates the Rewarding Properties of Psychostimulant Drugs in Mice
por: Egecioglu, Emil, et al.
Publicado: (2013)

The Glucagon-Like Peptide 1 Analogue Exendin-4 Attenuates the Nicotine-Induced Locomotor Stimulation, Accumbal Dopamine Release, Conditioned Place Preference as well as the Expression of Locomotor Sensitization in Mice
por: Egecioglu, Emil, et al.
Publicado: (2013)

Ghrelin increases intake of rewarding food in rodents
por: Egecioglu, Emil, et al.
Publicado: (2010)

Long-term treatment with a glucagon-like peptide-1 receptor agonist reduces ethanol intake in male and female rats
por: Vallöf, Daniel, et al.
Publicado: (2020)

Activation of glucagon‐like peptide‐1 receptors and skilled reach foraging
por: Vestlund, Jesper, et al.
Publicado: (2020)

An amylin analogue attenuates alcohol-related behaviours in various animal models of alcohol use disorder
por: Kalafateli, Aimilia Lydia, et al.
Publicado: (2019)

Ghrelin receptor antagonism attenuates cocaine- and amphetamine-induced locomotor stimulation, accumbal dopamine release, and conditioned place preference
por: Jerlhag, Elisabet, et al.
Publicado: (2010)

The Anorexigenic Peptide Neuromedin U (NMU) Attenuates Amphetamine-Induced Locomotor Stimulation, Accumbal Dopamine Release and Expression of Conditioned Place Preference in Mice
por: Vallöf, Daniel, et al.
Publicado: (2016)

Blockade of growth hormone secretagogue receptor 1A signaling by JMV 2959 attenuates the NMDAR antagonist, phencyclidine-induced impairments in prepulse inhibition
por: Engel, Jörgen A., et al.
Publicado: (2015)

Role of ghrelin in food reward: impact of ghrelin on sucrose self-administration and mesolimbic dopamine and acetylcholine receptor gene expression
por: Skibicka, Karolina P, et al.
Publicado: (2012)

Peripherally Circulating Ghrelin Does Not Mediate Alcohol‐Induced Reward and Alcohol Intake in Rodents
por: Jerlhag, Elisabet, et al.
Publicado: (2014)

Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis
por: Sawada, Noritaka, et al.
Publicado: (2020)

Hedonic and incentive signals for body weight control
por: Egecioglu, Emil, et al.
Publicado: (2011)

Glucagon Receptor Antagonism Ameliorates Progression of Heart Failure
por: Gao, Chen, et al.
Publicado: (2019)

The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies
por: Jerlhag, Elisabet
Publicado: (2023)

The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE(−/−) and LDLr(−/−) Mice by a Mechanism That Includes Inflammatory Pathways
por: Rakipovski, Günaj, et al.
Publicado: (2018)

Role of Appetite-Regulating Peptides in the Pathophysiology of Addiction: Implications for Pharmacotherapy
por: Engel, Jörgen A., et al.
Publicado: (2014)

The Global Transcriptional Response of Isolated Human Islets of Langerhans to Glucagon-Like Peptide-1 Receptor Agonist Liraglutide
por: Zhao, Xiaoning, et al.
Publicado: (2012)

The impact of the glucagon‐like peptide 1 receptor agonist liraglutide on the streptozotocin‐induced diabetic mouse kidney proteome
por: Liljedahl, Leena, et al.
Publicado: (2019)

Effects of insulin and the glucagon‐like peptide 1 receptor agonist liraglutide on the kidney proteome in db/db mice
por: Liljedahl, Leena, et al.
Publicado: (2017)

Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon‐like peptide‐1/glucagon receptor agonist SAR425899 in comparison with liraglutide
por: Schiavon, Michele, et al.
Publicado: (2021)

Liraglutide Lowers Endothelial Vascular Cell Adhesion Molecule-1 in Murine Atherosclerosis Independent of Glucose Levels
por: Punjabi, Mukesh, et al.
Publicado: (2022)

Glucagon-Like Peptide-1–Mediated Cardioprotection Does Not Reduce Right Ventricular Stunning and Cumulative Ischemic Dysfunction After Coronary Balloon Occlusion
por: Giblett, Joel P., et al.
Publicado: (2019)

Potential of AT(1)-R-Biased Agonists in Pediatric Heart Failure
por: Port, J. David
Publicado: (2020)

Genetic Testing in Familial Hypercholesterolemia: Strengthening the Tools, Reinforcing Efforts, and Diagnosis
por: Abifadel, Marianne S., et al.
Publicado: (2021)

Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes.
por: Lu, Nan, et al.
Publicado: (2015)

Glucagon-like peptide-1 receptor agonist, liraglutide, attenuated retinal thickening in spontaneously diabetic Torii fatty rats
por: Inoue, Kazuho, et al.
Publicado: (2022)

PM426. Effect of a glucagon-like peptide 1 (GLP-1) receptor agonist, liraglutide, on cognition and body weight during antipsychotic treatment
por: Babic, I, et al.
Publicado: (2016)

An Oral Selective Alpha-1A Adrenergic Receptor Agonist Prevents Doxorubicin Cardiotoxicity
por: Beak, Ju Youn, et al.
Publicado: (2017)

Leveraging FPR2 Agonists to Resolve Inflammation and Improve Outcomes Following Myocardial Infarction
por: Koenig, Andrew L., et al.
Publicado: (2021)

Effects of the glucagon-like peptide-1 receptor agonist liraglutide in juvenile transgenic pigs modeling a pre-diabetic condition
por: Streckel, Elisabeth, et al.
Publicado: (2015)

Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis
por: Meurot, C., et al.
Publicado: (2022)

Preservation of Post-Infarction Cardiac Structure and Function via Long-Term Oral Formyl Peptide Receptor Agonist Treatment
por: García, Ricardo A., et al.
Publicado: (2019)

Liver X receptor agonist T0901317 inhibits the migration and invasion of non-small-cell lung cancer cells in vivo and in vitro
por: Lou, Rui, et al.
Publicado: (2019)

Glucagon-Like Peptide-1 Protects Against Atrial Fibrillation and Atrial Remodeling in Type 2 Diabetic Mice
por: Bohne, Loryn J., et al.
Publicado: (2023)

In Vivo Reactive Oxygen Species Detection With a Novel Positron Emission Tomography Tracer, (18)F-DHMT, Allows for Early Detection of Anthracycline-Induced Cardiotoxicity in Rodents
por: Boutagy, Nabil E., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_262jgsmpsc3fdnqlotr7q4u362